Loading...

Financial Summary


CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP)

Healthcare
Buy
B+
Market Info
Financial Info
Financial Modelling
Symbol CRSP
Price 46.51$
Beta 3.08
Volume Avrg. 1.15M
Market Cap 2.23B
Shares (2018) 47,964.37K
Last Div 0
Dividend Yield -
DCF Unlevered -
DCF Levered -
ROE -42.07% Strong Sell
ROA -36.09% Strong Sell
Operating Margin -5087.80% Strong Sell
Debt / Equity 0.00% Neutral
P/E - Neutral
P/B 3.77 Strong Buy

Income Statement

Download CRSP income statement Download CRSP income statement
Year 20142015201620172018
Revenue -0.255.1641.003.12
Cost of Revenue -----
Gross Profit -0.255.1641.003.12
R&D Expenses 1.5112.5742.2469.80113.77
Sales, General and Administrative Expense 5.1113.4031.0635.8448.29
Operating Expenses 6.6325.9873.29105.64162.07
Operating Income -6.63-25.73-68.13-64.65-158.94
Interest Expense -0.118.05--
Earnings before Tax -6.33-25.50-22.69-66.61-164.43
Income Tax Expense -0.060.010.481.750.55
Net Income -6.26-25.50-23.18-68.36-164.98
Net Income - Non-Controlling int -0.54-0.33-0.03--
Net Income - Discounted ops -----
Net Income Com -7.01-25.50-23.18-68.36-164.98
Preferred Dividends 0.74----
Earnings Per Share Basic 1.97-5.06-1.89-1.71-3.44
Earnings Per Share Diluted 1.97-5.06-1.89-1.71-3.44
Weighted Average Shares Outstanding 3.565.0412.2640.0647.96
Weighted Average Shares Outstanding (Diluted) 3.565.0412.2640.0647.96
Dividend per Share -----
Gross Margin -1.001.001.001.00
EBITDA Margin --102.27-2.66-1.55-51.51
EBIT Margin --102.79-2.84-1.62-52.63
Profit Margin --103.25-4.49-1.67-52.81
Free Cash Flow margin -0.00-0.00-0.00-0.00
EBITDA -6.29-25.26-13.72-63.58-160.91
EBIT -6.33-25.39-14.64-66.61-164.43
Consolidated Income -6.80-25.83-23.20-68.36-164.98
Earnings Before Tax Margin --103.22-4.39-1.62-52.63
Net Profit Margin --103.25-4.49-1.67-52.81

Balance Sheet Statement

Download CRSP income statement Download CRSP income statement
Year 20142015201620172018
Cash and cash equivalents 0.99156.66318.67242.91459.81
Short-term investments -----
Cash and short-term investments 0.99156.66318.67242.91459.81
Receivables -0.343.162.630.09
Inventories -----
Property, Plant & Equipment Net -1.3321.0318.8618.50
Goodwill and Intangible Assets 0.510.450.400.340.29
Long-term investments -----
Tax assets -----
Total non-current assets 0.09113.8790.1269.0069.08
Total current assets 0.562.5824.7722.9622.62
Total assets 1.53159.42344.96271.35489.02
Payables 0.211.584.571.645.07
Short-term debt -----
Total current liabilities 2.1510.1522.0014.5127.75
Long-term debt -38.34---
Total debt -38.34---
Deferred revenue -75.0977.6556.9357.78
Tax Liabilities 0.010.080.020.350.40
Deposit Liabilities -----
Total non-current liabilities 0.09113.8790.1269.0069.08
Total liabilities 2.23124.03112.1283.5196.82
Other comprehensive income -0.00-0.01-0.030.01-0.01
Retained earnings (deficit) -8.40-33.91-57.08-125.44-291.57
Total shareholders equity -7.12-29.10232.85187.83392.19
Investments -----
Net Debt -0.99-118.33-318.67-242.91-459.81
Other Assets -0.03-0.16-1.642.856.50
Other Liabilities 1.948.5717.4312.8722.68

Cash Flow Statement

Download CRSP income statement Download CRSP income statement
Year 20142015201620172018
Depreciation & Amortization 0.040.130.933.023.52
Stock-based compensation 0.693.6810.8418.8734.98
Operating Cash Flow -4.7959.43-52.86-70.09-96.24
Capital Expenditure --1.15-3.02-7.81-2.77
Acquisitions and disposals -----
Investment purchases and sales ---0.10-0.50-
Investing Cash Flow -----
Insurance (repayment) of debt -----
Insurance (buybacks) of shares -----
Dividend payments -----
Financing Cash Flow 5.1296.73183.222.61315.93
Effect of forex changes on cash 0.250.01-0.230.04-0.02
Net cash flow / Change in cash 0.58155.02162.01-75.76216.90
Free Cash Flow -4.7958.27-55.88-77.91-99.01
Net Cash/Marketcap 0.000.000.000.000.00

Retained Earning Schedule

Year 20142015201620172018
Retained Earnings (Previous Year) --8-34-57-125
Net Income -6-26-23-68-165
Stock Dividends -2----1
Divident Paid -----
Retained Earnings -8-34-57-125-292
Year 20142015201620172018
Gross PPE --12119
Annual Depreciation -22362
Capital Expenditure --1-3-8-3
Net PPE -1211919

Intangible and Goodwill Schedule

Year 20142015201620172018
Intangible and Goodwill (Previous Year) -1000
New Purchases ---0-1-
Intangible and Goodwill 10000
CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP)

46.51
0.16 (+0.35%)

About


Samarth Kulkarni
Healthcare
Biotechnology
NASDAQ Global Market

CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.